荃信生物-B已购回248.78万股普通股作为库存股

Core Viewpoint - The company believes its current stock price is significantly undervalued and aims to enhance market confidence and investment value through share buybacks [1] Group 1: Share Buyback Details - The company has repurchased a total of 2.4878 million ordinary shares as treasury stock from November 6, 2025, to the date of the announcement [1] - The repurchased shares represent approximately 1.10% of the company's existing issued share capital as of the announcement date [1] - The total amount involved in the buyback is approximately HKD 50.75 million, excluding commissions and other expenses [1]